Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 16Sarcoma 6Lymphoid 2Breast 2Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 18Biopsy 18pembrolizumab 13Magnetic Resonance Spectroscopy 12Paclitaxel 8X-Rays 5Bevacizumab 5trastuzumab deruxtecan 4durvalumab 4atezolizumab 4Standard of Care 4Fluorouracil 4Carboplatin 4Capecitabine 4Blood Specimen Collection 4nilotinib 3ipatasertib 3Taxes 3Radiotherapy 3Pemetrexed 3Oxaliplatin 3Nivolumab 3Leucovorin 3Exercise 3Cetuximab 3trametinib 2olaparib 2inavolisib 2dostarlimab 2copanlisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
liposomal doxorubicin × Tumor-Agnostic × 30 days × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡